Unipharma.ch

"Children 4 to 6 years-old can receive five or more vaccinations in a single visit, which can be stressful for parents and vaccinators," said William P. Hitchcock, MD, Assistant Clinical Professor of Pediatrics, School of Medicine. "By reducing the number of shots given in one visit, combination vaccines like Kinrix may make it easier for kids to meet school vaccination requirements and CDC recommendations."

Clinical studies of Kinrix have demonstrated that this new combination vaccine offers similar protection to the separately administered Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) and Inactivated Poliovirus (IPV) vaccines, with a comparable safety profile. These results were confirmed in the pivotal Phase III trial of Kinrix, which was a randomized, controlled study conducted in the U.S. in which 3,156 children 4 to 6 years of age were vaccinated with Kinrix. All children studied had previously received four doses of DTaP (INFANRIX) and three doses of IPV (IPOL). All children in the study also received the second dose of U.S.-licensed measles, mumps and rubella (MMR) vaccine (M-M-RII) at the same time.

"Kinrix contains the same DTaP and IPV components used in INFANRIX and PEDIARIX, two vaccines which have been used by doctors in the U.S. for many years," said Wayde M. Weston, Ph.D., Director, U.S. Clinical Research and Development/Medical Affairs, GlaxoSmithKline. "With the introduction of Kinrix, eligible 4 to 6 year-olds can receive protection against four serious diseases with one less shot."

Source:
http://www.drugs.com

More informations:
http://www.drugs.com/newdrugs/fda-approves-kinrix-new-combination-vaccine-children-1035.html